You searched for Semma

Biotech Talks #ISSCR2015: StemCells Inc, Semma, ViaCyte, & Le Blanc

June 27, 2015 / Heather Main / 1 Comment

The path to the clinic is a slow and arduous activity, frustrating not only to the researcher and patient, but investors and biotech companies. Successful clinical translation of technologies requires a balance of science, streamlined translation and funding. To develop fantastic science and then realise the most important components cannot be adapted to the clinical […]

Biotech Talks #ISSCR2015: StemCells Inc, Semma, ViaCyte, & Le Blanc Read More »

New biotech Semma Therapeutics stem cell diabetes arena

March 25, 2015 / Professor Paul Knoepfler, Ph.D. / 2 Comments

A new biotech startup, Semma Therapeutics, announced that it seeks to fight diabetes via translating technology from the lab of Doug Melton at Harvard to the clinic. Update: Note that the firm was recently acquired by Vertex. Another major player in cell therapy-based arena for Diabetes is most likely good news for patients. Quoted in the Boston

New biotech Semma Therapeutics stem cell diabetes arena Read More »

Weekly reads: Vertex stem cells for diabetes, storing iPS cells on the Moon, science hype award nominees

September 1, 2024 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

Felicia Pagliuca, stem cells for diabetes

How is research looking on stem cells for diabetes? I’m feeling more encouraged about the clinical research in that area. Before we jump into that let’s talk about two other things. The big news of the week was the felony plea deal by Liveyon’s John Kosolcharoen to charges related to marketing an unapproved cell therapy

Weekly reads: Vertex stem cells for diabetes, storing iPS cells on the Moon, science hype award nominees Read More »

Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics

January 14, 2024 / Professor Paul Knoepfler, Ph.D. / 5 Comments

The biotechs Vertex and CRISPR Therapeutics have an interesting relationship as biotechs. They are partners are multiple levels but also are very different as companies including in size. There’s been a key development in one of their partnerships. Before we jump into that, please check out the video version of my 20 stem cell and

Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics Read More »

3 cell therapy companies doing well: Vertex, Vericel, & Regeneron

November 15, 2023 / Professor Paul Knoepfler, Ph.D. / 5 Comments

Cell therapy companies face many hurdles. I wrote recently about four cell therapy biotechs that have been really struggling. Blogging here at The Niche for more than a dozen years, I’ve seen many companies even go under. That’s bad news for the field, for patients, and for investors. Today I wanted to highlight some cell therapy

3 cell therapy companies doing well: Vertex, Vericel, & Regeneron Read More »

2023 stem cell & regenerative medicine predictions

December 28, 2022 / Professor Paul Knoepfler, Ph.D. / 1 Comment

Toward the end of each year, I make stem cell & regenerative medicine predictions for the coming year. It’s a fun tradition here on The Niche that goes way back. The stem cell field has changed dramatically as reflected in each year’s predictions. Here’s a list of past predictions with my grades of how they

2023 stem cell & regenerative medicine predictions Read More »

ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes

July 26, 2022 / Professor Paul Knoepfler, Ph.D. / 2 Comments

When I’m asked about the most promising areas of stem cell clinical research, cell therapy for type I diabetes is near the top including work by a biotech called ViaCyte. Other firms are in the mix too, boosting the overall odds of success in the coming decade. It’s really that promising even though there are

ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes Read More »

Vertex upbeat on 1st stem cell therapy for diabetes trial participant

October 19, 2021 / Professor Paul Knoepfler, Ph.D. / 14 Comments

“While still early, these results support the continued progression of our VX-880 clinical studies, as well as future studies using our encapsulated islet cells, which hold the potential to be used without the need for immunosuppression,” said Bastiano Sanna, Ph.D., executive vice president and chief of cell and genetic therapies at Vertex.

It’s hard in the cell therapy field not to get excited even with bits of seemingly encouraging news but with N=1 reports we have to be very cautious and that’s the case with news from Vertex on their 1st stem cell therapy for diabetes trial participant. Vertex stem cell therapy for diabetes VX-880: N=1 This

Vertex upbeat on 1st stem cell therapy for diabetes trial participant Read More »

Stem cell therapy for diabetes updates: expected IPO, CRISPR, new pubs, more

June 22, 2021 / Professor Paul Knoepfler, Ph.D. / 3 Comments

The idea of stem cell therapy for diabetes is both exciting and in a way practical. By that I mean that there’s a good common sense foundation here. The idea of stem cell therapy for diabetes What do I mean? If medical researchers can replace lost beta cells in the pancreas using stem cell-produced beta

Stem cell therapy for diabetes updates: expected IPO, CRISPR, new pubs, more Read More »

ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more

September 25, 2019 / Professor Paul Knoepfler, Ph.D. / 9 Comments

ViaCyte is one of the most exciting stem cell and regenerative medicine biotech companies so I like to try to check in with them regularly. Today’s post is my new interview with ViaCyte leader Paul Laikind on recent developments. We had a great chat about the science and how things are looking upbeat for the

ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more Read More »

Search Results for: Semma